Meitav Mutual Funds Ltd. has recently announced that it has increased stake in Protalix BioTherapeutics Inc. (AMEX:PLX) by 0.06%. After grabbing 0.24 million shares, the institutional investor is now in possession of 150.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.43% having worth around $0.47 million. Moreover, Renaissance Technologies LLC increased its share by 0.11 million to have a control over 0.22 million shares. And Citadel Securities LLC raised its holdings to 65750.0 shares by acquiring 0.12 million shares or 0.22% of the stake.
Protalix BioTherapeutics Inc. (PLX) concluded trading on 03/16/23 at a closing price of $2.06, with 0.96 million shares of worth about $1.97 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 89.86% during that period and on Thursday the price saw a gain of about 1.48%. Currently the company’s common shares owned by public are about 57.38M shares, out of which, 48.36M shares are available for trading.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 2 times over the past 12 months. They bought 178,000 shares in 2 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
FCP Medical – BioHealth, APO Medical Opportunities, and RIM Global – Bioscience are the top 3 mutual funds which are holding stakes in Protalix BioTherapeutics Inc. FCP Medical – BioHealth is currently holding 0.97 million shares of worth totaling $1.89 million. The company recently came buying 0.0 shares which brought its stake up to 1.70% of the company’s outstanding shares. RIM Global – Bioscience, after buying 0.16 million shares, have now control over 0.28% of the stake in the company. It holds 0.0 shares of worth $0.31 million.
Protalix BioTherapeutics Inc. (AMEX: PLX) started trading at $2.08, above $0.05 from concluding price of the previous day. However, the stock later moved at a day high price of 2.1100, or with a gain of 1.48%. Stock saw a price change of -0.48% in past 5 days and over the past one month there was a price change of 33.77%. Year-to-date (YTD), PLX shares are showing a performance of 50.36% which increased to 136.78% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.85 but also hit the highest price of $2.21 during that period. The average intraday trading volume for Protalix BioTherapeutics Inc. shares is 956.87K. The stock is currently trading 9.87% above its 20-day simple moving average (SMA20), while that difference is up 21.92% for SMA50 and it goes to 64.66% higher than SMA200.
Meitav Mutual Funds Ltd. acquired 0.24 million shares of Protalix BioTherapeutics Inc. having value of about $0.47 million. Data submitted at the U.S SEC by Meitav Mutual Funds Ltd. revealed that the firm now holds 150.0 shares in the company valued at close to $309.0, or have control over 0.06% stake in the company. Protalix BioTherapeutics Inc. (AMEX: PLX) currently have 57.38M outstanding shares and institutions hold larger chunk of about 8.64% of that. Holding of mutual funds in the company is about 5.32% while other institutional holders and individual stake holders have control over 9.74% and 3.62% of the stake respectively.
The stock has a current market capitalization of $118.20M. It has posted earnings per share of -$0.27 in the same period. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PLX, volatility over the week remained 8.62% while standing at 7.22% over the month.
Analysts are in expectations that Protalix BioTherapeutics Inc. (PLX) stock would likely to be making an EPS of -$0.15 in the current quarter, while forecast for next quarter EPS is $0 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.15 which is -$0.15 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.09 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 145.20% while it is estimated to increase by 357.10% in next year.
Analysts at 1 brokerage firms have issued recommendations for the Protalix BioTherapeutics Inc. (PLX)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on June 08, 2020 offering a Buy rating for the stock and assigned a target price range of between $3 and $11 to it. Coverage by Rodman & Renshaw stated Protalix BioTherapeutics Inc. (PLX) stock as a Buy in their note to investors on April 17, 2017, suggesting a price target of $5 for the stock. On April 04, 2016, Rodman & Renshaw Initiated their recommendations, while on April 23, 2015, Jefferies Upgrade their ratings for the stock with a price target of $2.60. Stock get a Buy rating from R. F. Lafferty on November 12, 2014.
